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Dalibor Pacik1,5, Mariana Plevova1,5, Lucie Urbanova2, Zuzana Lackova3,4, Vladislav Strmiska3, 
Alois Necas2, Zbynek Heger3,4 & Vojtech Adam  3,4
The hypothesis that dogs can detect malignant tumours through the identification of specific molecules 
is nearly 30 years old. To date, several reports have described the successful detection of distinct types 
of cancer. However, is still a lack of data regarding the specific molecules that can be recognized by a 
dog’s olfactory apparatus. Hence, we performed a study with artificially prepared, well-characterized 
urinary specimens that were enriched with sarcosine, a widely reported urinary biomarker for prostate 
cancer (PCa). For the purposes of the study, a German shepherd dog was utilized for analyses of 60 
positive and 120 negative samples. Our study provides the first evidence that a sniffer dog specially 
trained for the olfactory detection of PCa can recognize sarcosine in artificial urine with a performance 
[sensitivity of 90%, specificity of 95%, and precision of 90% for the highest amount of sarcosine 
(10 µmol/L)] that is comparable to the identification of PCa-diagnosed subjects (sensitivity of 93.5% and 
specificity of 91.6%). This study casts light on the unrevealed phenomenon of PCa olfactory detection 
and opens the door for further studies with canine olfactory detection and cancer diagnostics.
Prostate cancer (PCa) remains the second most frequent malignant disease in men and the third cause of death 
among men in the US and Western Europe, with 1.1 million newly diagnosed cases in 2012, representing 15% of 
all oncological diagnoses in men1. Although it has been almost 30 years from establishing the prostate-specific 
antigen (PSA) in clinical practice, PCa diagnostics and screening remain inefficient and rely on the quantitation 
of PSA combined with a digital rectal examination (DRE). Hence, substantial effort is being put into discovering 
new approaches for PCa detection, which ideally should be sufficiently reliable, PCa-specific and sensitive for 
early-stage detection2.
In our previous study, we demonstrated that a specially trained sniffer dog can reach high sensitivity (93.5%) 
and specificity (91.6%) in diagnosing histologically confirmed PCa using its olfactory abilities by sniffing urinary 
specimens from patients with PCa3. The hypothesis that dogs may be able to detect malignant tumours on the 
basis of odour is not new and was first put forward by Williams and Pembroke in 19894. From that time, several 
reports have been published describing the olfactory identification of cancers of the bladder5, breast and lung6, 
skin7 or prostate3.
Despite these promising results, to our knowledge, there is no information regarding the substances that are 
responsible for canine olfactory recognition. The most investigated substances are volatile organic compounds 
(VOCs), which can be produced due to tumour metabolic shifts8. Heterogeneous groups of VOCs can be then 
detected in sweat, breath, urine or stool, and these chemical groups include acids, alcohols, ketones, aldehydes, 
amines and others9.
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We hypothesized that the olfactory detection of PCa based on the sniffing of urinary specimens should be 
enabled by the presence of sarcosine. Sarcosine (N-methylglycine) is a reported biomarker for PCa, of which an 
increased urinary level and potential for non-invasive detection of early-stage PCa was delineated in 2009 by 
Sreekumar et al.10. If the olfactory detection of PCa depends on the amount of sarcosine in a complex mixture 
of urinary compounds, then a trained dog should be able to recognize the artificial urine with the addition of 
sarcosine. Hence, the aim of the present study is to perform olfactory analyses of artificially prepared urinary 
specimens containing distinct, physiologically relevant concentrations of sarcosine with the same dog that has an 
excellent accuracy for PCa diagnostics, per our previously published study3.
Results
In three stages from August 2016 to May 2017, the dog gradually carried out olfactory analyses of 60 positive and 
120 negative samples. The stages differed only in the amount of added sarcosine in the positive samples, while the 
composition of the negative samples remained constant throughout all stages. Table 1 illustrates the overview of 
the grades of olfactory identification of positive samples across all stages. Table 2 demonstrates the classification 
of all olfactory analysis results, which were subsequently employed for statistical processing.
In the first stage, when the amount of sarcosine in the artificial urine was 1 µmol/L, the sensitivity of olfac-
tory detection was 85% with 92.5% specificity. In the second stage, when the concentration of added sarcosine 
decreased to 0.1 µmol/L, the olfactory analysis reached a sensitivity of 70% and a specificity of 85%. Finally, in the 
third stage with the highest amount of added sarcosine (10.0 µmol/L), we identified the highest sensitivity (90%) 
and specificity (95%), underpinning the importance of sarcosine in the success rate of olfactory analyses.
Using these results, the predictive value of the positive test (or precision) is 90% with an LR of 18 for posi-
tive samples and 10.5 for negative samples. These values show the exceptional accuracy of the sniffer dog and 
demonstrate that sarcosine could be one of the pivotal urinary molecules that are recognized by a dog’s olfactory 
abilities. Importantly, we also verified that sarcosine concentration is not decreased during olfactory analysis due 
to biochemical instability and degradation (Table 3).
Discussion
Scent is a well-developed sense in most animal species. Distinct odours are detected by olfactory receptors (ORs) 
expressed in the olfactory epithelium of the nasal cavity. In 2014, Niimura et al. delineated the numbers of orthol-
ogous genes encoding ORs, and the dog (Canis lupus f. familiaris) ranked 9th place with 811 genes11. For compari-
son, 1st place belongs to the African elephant (Laxodonta africana) with 1948 OR genes. Hence, the dog is the best 
choice for olfactory detection because of two key aspects: i) the dog is capable of intensive training, and ii) the dog 
can be easily handled while detecting very low concentrations of a target substance12.
In 2008, Gordon et al. attempted to expand the dog’s exceptional olfactory capabilities to the area of PCa detec-
tion13. However, due to procedural errors, the study did not bring positive results. Despite that, the publication 
Grade 1st stage 2nd stage 3rd stage
1 8 6 10
2 9 8 8
3 3 6 2
Table 1. Identification grading of positive samples (with added sarcosine) in three stages.
1st stage 2nd stage 3rd stage
TP 17 14 18
FP 3 6 2
FN 3 6 2
TN 37 34 38
Table 2. Classification of the sarcosine olfactory detection results. TP - true positive, FP - false positive, FN - 
false negative, TN - true negative.
Sarcosine (µmol/L) n
1st stage 2nd stage 3rd stage
BOA* AOA** BOA AOA BOA AOA
Mean ± SD Mean ± SD Mean ± SD
0.1 20 0.095 ± 0.04 0.097 ± 0.08 0.11 ± 0.06 0.099 ± 0.01 0. 10 ± 0.02 0.098 ± 0.01
1.0 20 1.01 ± 0. 16 0.97 ± 0.11 0.98 ± 0.11 1.04 ± 0.14 0.95 ± 0.08 0.97 ± 0.10
10.0 20 9.71 ± 1.26 10.06 ± 1.87 10.04 ± 2.01 9.99 ± 1.48 10.05 ± 1.99 10.10 ± 2.68
Table 3. IEC-Vis verification of sarcosine stability before and after olfactory analyses. *BOA - before olfactory 
analysis. **AOA - after olfactory analysis.
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was significant for the success of future studies. In 2011, the first successful olfactory analysis of PCa was per-
formed by Cornu et al.14. The study demonstrated that a specially trained dog can detect PCa from urinary spec-
imens with a sensitivity and specificity of 91%. Similar results have been achieved in our pilot study (sensitivity 
of 93.5% and specificity of 91.6%)3 and in a study by Taverna et al. who used two dogs and reached a sensitivity 
of 98.6–100% and a specificity of 97.6–98.7%. All abovementioned studies demonstrate that through intensive 
training, the dog’s exceptional olfactory apparatus can recognize PCa, most likely due to the presence of urinary 
VOCs. Despite that, to our knowledge, no one has performed an experiment with a well-characterized artificial 
matrix to identify the targets for olfactory detection.
Hence, the answer to the question: “What do sniffer dogs really smell in the urine?” could provide significant 
insight into the potential of non-invasive biomarkers for PCa laboratory diagnostics, which currently rely on PSA, 
which has a relatively poor discriminating ability in men with symptomatic benign prostatic hyperplasia15. This 
often results in false positivity and unnecessary biopsies. Regardless, even in 2017, there is no clue to which of the 
urinary compounds is responsible for a high performance of PCa olfactory detection.
Our study was performed in regard to the excellent results of our sniffer dog in detecting PCa from the 2015 
study3 and the fact that urinary sarcosine appears to be a potential PCa biomarker, whose concentrations are 
increased in the urine of PCa-diagnosed patients10,16. Because we are using an animal as a “sensory device”, several 
issues should be mentioned. First, we did not carry out any training of the dog’s olfactory apparatus to identify 
sarcosine; hence, the dog that was trained to detect PCa could fluently follow the sniffing of artificially prepared 
urine. The experiments also had several pitfalls. There was a potential concern that after a new experience, the dog 
would not be able to continue with the detection of PCa. We also considered using sarcosine dissolved in water; 
however, due to concerns that a new solvent would confuse the dog trained to sniff human urine, we avoided this 
option. For the same reason, we avoided the use of female urine, which can confuse the dog due to the presence 
of oestrogen hormones. Hence, we decided to use artificial urine, which mimics human urine and its chemical 
composition is fully characterized. To fully imitate real urine, additions of sarcosine were selected to correspond 
to the values of sarcosine in urinary specimens, which have been identified in PCa-diagnosed patients17,18.
One advantage of our study is that we used the same dog for the detection of PCa and sarcosine. This enabled 
a direct comparison between sensitivity and specificity, which are significantly comparable, particularly when 
detecting the highest amount of sarcosine (sensitivity of 93.5% and specificity of 91.6% for PCa vs. 90% and 95% 
for sarcosine, respectively). The credibility of our results is further supported by olfactory analyses being carried 
out immediately after the preparation of artificial urine without freezing, which results in sarcosine degradation. 
Importantly, the artificial urine did not contain any enzymes that degrade sarcosine (sarcosine dehydrogenase 
and sarcosine oxidase) to yield glycine16, and thus, sarcosine remained stable throughout the olfactory detection 
series as shown by IEC-Vis. Notably, the achieved results may be biased due to the relatively small number of 
analysed specimens; however, the contribution of sarcosine to the success rate of olfactory detection is clear, as 
well as its dependence on sarcosine concentration.
Materials and Methods
Chemicals. All chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) at American Chemical 
Society (ACS) purity, unless noted otherwise.
The dog and its training. For the purposes of the study, a German shepherd dog named Agata Jankari, born 
on May 1, 2012, was utilized. She began a special training programme at seven months of age. Prior to that, she 
underwent basic obedience training and scent work training19. The training of the dog at a young age to utilize its 
olfactory abilities to diagnose PCa was based on the positive reinforcement method using a clicker as described 
in our previous study3. This method consists of marking and rewarding desired behaviours, which are indicated 
by a clicker and immediately rewarded using a treat or a game with a toy.
Preparation of artificial urinary specimens with the addition of sarcosine. The urine medium was 
based on the analyses of constituents in common human urine, of which the midpoint values of the ranges given 
for each component have been used. Each batch was freshly prepared prior analysis as 0.5 L of solution containing 
250 mL of distilled water (v/v), 1.9 g of potassium chloride (w/v), 4.25 g of sodium chloride (w/v), 12.25 g of urea 
(w/v), 0.07 g of uric acid (w/v), 0.52 g of magnesium sulphate heptahydrate (w/v), 0.52 g of citric acid (w/v), 0.17 g 
of ascorbic acid (w/v), 0.59 of potassium dihydrogen phosphate (w/v), 0.17 g of calcium chloride (w/v), 0.0012 g 
of iron(II) sulphate (w/v), 1.6 g of sodium sulphate (w/v), 0.7 g of ammonium chloride (w/v), 0.7 g of creatinine 
(w/v), 0.32 g of sodium hydroxide (w/v) (added slowly), 0.235 g of sodium bicarbonate (w/v), 0.14 mL of 18 M 
sulphuric acid (v/v); to add a small amounts of nucleic acids and trace elements, we added 0.005 g of yeast extract 
(w/v). Finally, 1 g of bacteriological peptone (w/v) was added for a mixture of amino acids. The mixture was 
brought to final volume (0.5 L) with water and had a pH of approximately 6.9. The resulting solution was sepa-
rated into 5-mL aliquots in opaque tubes, and either non-spiked aliquots or aliquots spiked with sarcosine (0.1, 
1.0 or 10.0 µmol/L) were immediately transported to the Small Animal Clinic, Faculty of Veterinary Medicine, 
University of Veterinary and Pharmaceutical Sciences. After 30 min of equilibration at room temperature, sam-
ples were prepared for subsequent olfactory analyses. Before and after the olfactory analyses, the amount of sar-
cosine in the artificial urine was verified using ion-exchange chromatography (IEC) with post-column ninhydrin 
derivatization and visible spectrophotometry (Vis) detection (IEC-Vis) according to our previous study20 to con-
trol for the possible degradation of sarcosine.
Olfactory analysis of artificial urinary samples. The methodology was based on our previous study 
regarding olfactory identification of the urine of PCa-positive subjects3. A sniffing series always contained one 
positive and two negative samples randomly placed on the floor. This prevented the dog to create a link between 
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a particular sample position and its positivity/negativity. Each series contained only three samples to fully main-
tain the concentration of the dog for olfactory analysis. This also allowed keeping a sufficient distance between 
analysed samples (at least 75 cm) to prevent fusion of odours, which could bias the analysis. Contrary to our pre-
vious study and the dog’s training, as a positive sample, laboratory-prepared artificial urine (detailed composition 
described above) with defined amount of sarcosine, ranging between 0.1 to 10.0 µmol/L, was used. As a negative 
control, we employed artificial urine without sarcosine. Samples (5 mL) were randomly positioned on the floor 
in uniform, opaque plastic beakers with a perforated lid. The beakers were fixed to the floor using non-perfumed 
adhesives (Pritt Multi Tack, Pritt, Dusseldorf, Germany) to prevent them from being knocked over. The dog han-
dler was familiar with the position of the positive samples to reward the dog in cases of correct identification. As 
reward, Lakse Kronch Treat with salmon oil (Henne Pet Food, Outrup, Denmark) was used. All methods were 
carried out in accordance with relevant guidelines and regulations. The experimental protocols were approved by 
Ethical Committee of University of Veterinary and Pharmaceutical Sciences Brno, Brno, CZ.
Grading for identification evaluation. After presenting samples to the dog, we evaluated its behaviour 
using three different grades as follows: grade 1, the sample was identified immediately without hesitation, i.e., the 
dog laid down by the sample while ignoring the other samples; grade 2, the sample was identified with a slight 
hesitation, i.e., the dog repeatedly sniffed it and then carried out the correct identification; grade 3, the sample was 
identified incorrectly, i.e., a false positive or false negative identification.
Descriptive statistics. The results from the olfactory identification sessions were analysed using statistical 
evaluation of the accuracy of the diagnostic assay, in which the diagnostic potential of the test was validated and 
compared with the verifiable status of the tested object. Specifically, in the cases of behavioural grades 1 and 2, the 
positive results were classified as true positive (TP) and the negative results as true negative (TN). In the case of 
behavioural grade 3, the results were classified as false negative (FN) or false positive (FP).
The sensitivity, the probability that the analysis will give a positive result, when the sample is genuinely posi-
tive was calculated as follows:
= + .Sensitivity TP TP FN(%) /( ) (1)
The specificity, the probability that the analysis will give a negative result, when the sample is genuinely nega-
tive was calculated as follows:
= + .Specificity TN FP TN(%) /( ) (2)
The predictive value (precision) of a positive test, the probability that a sample is positive when the olfactory 
analysis gives a positive result, was calculated as follows:
= + .Predictive value of a positive test TP TP FP/( ) (3)
The likelihood ratio (LR) for a positive result (LR+) represents the probability ratio that the positive sample 
is diagnosed as a positive and the probability ratio that the negative sample is misidentified as positive, and LR+ 
was calculated as follows:
+ = − .LR sensitivity specificity/(1 ) (4)
The LR for a negative result (LR-) represents the probability ratio that the negative sample is diagnosed as negative 
and the probability ratio that the positive sample is misidentified as negative, and LR- was calculated as follows:
−= − .LR sensitivity specificity(1 )/ (5)
Generally, a high-quality diagnostic test is defined by an LR + > 10 and an LR− > 0.1.
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